Exposure to valsartan products containing nitrosamine impurities in the US, Canada, and Denmark
View ORCID ProfileEfe Eworuke, Mayura U. Shinde, Laura Hou, J. Michael Paterson, Peter Bjødstrup Jensen, Judith C. Maro, Ashish Rai, Anton Pottegård, Daniel Scarnecchia, Yuanling Liang, Deborah Johnson, Robert W. Platt, Hana Lee, Marie C. Bradley
doi: https://doi.org/10.1101/2023.12.05.23299542
Efe Eworuke
1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
PhDMayura U. Shinde
2Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
Laura Hou
2Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
J. Michael Paterson
3Canadian Network for Observational Drug Effect Studies (CNODES), Montréal, QC, CA
MScPeter Bjødstrup Jensen
4University of Southern Denmark, Odense, DK
PhDJudith C. Maro
2Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
PhDAshish Rai
2Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
PhD MSPH, MBBSAnton Pottegård
4University of Southern Denmark, Odense, DK
PhDDaniel Scarnecchia
2Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
MPIAYuanling Liang
1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
PhDDeborah Johnson
1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
PhDRobert W. Platt
3Canadian Network for Observational Drug Effect Studies (CNODES), Montréal, QC, CA
PhDHana Lee
1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
PhDMarie C. Bradley
1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
PhD, MPharm, MSc.PH
Data Availability
Data cannot be shared with external stakeholders due to confidentiality agreements.
Posted December 07, 2023.
Exposure to valsartan products containing nitrosamine impurities in the US, Canada, and Denmark
Efe Eworuke, Mayura U. Shinde, Laura Hou, J. Michael Paterson, Peter Bjødstrup Jensen, Judith C. Maro, Ashish Rai, Anton Pottegård, Daniel Scarnecchia, Yuanling Liang, Deborah Johnson, Robert W. Platt, Hana Lee, Marie C. Bradley
medRxiv 2023.12.05.23299542; doi: https://doi.org/10.1101/2023.12.05.23299542
Exposure to valsartan products containing nitrosamine impurities in the US, Canada, and Denmark
Efe Eworuke, Mayura U. Shinde, Laura Hou, J. Michael Paterson, Peter Bjødstrup Jensen, Judith C. Maro, Ashish Rai, Anton Pottegård, Daniel Scarnecchia, Yuanling Liang, Deborah Johnson, Robert W. Platt, Hana Lee, Marie C. Bradley
medRxiv 2023.12.05.23299542; doi: https://doi.org/10.1101/2023.12.05.23299542
Subject Area
Subject Areas
- Addiction Medicine (349)
- Allergy and Immunology (668)
- Allergy and Immunology (668)
- Anesthesia (181)
- Cardiovascular Medicine (2648)
- Dermatology (223)
- Emergency Medicine (399)
- Epidemiology (12228)
- Forensic Medicine (10)
- Gastroenterology (759)
- Genetic and Genomic Medicine (4103)
- Geriatric Medicine (387)
- Health Economics (680)
- Health Informatics (2657)
- Health Policy (1005)
- Hematology (363)
- HIV/AIDS (851)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (436)
- Neurology (3882)
- Nursing (209)
- Nutrition (577)
- Oncology (2030)
- Ophthalmology (585)
- Orthopedics (240)
- Otolaryngology (306)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1115)
- Primary Care Research (452)
- Public and Global Health (6527)
- Radiology and Imaging (1403)
- Respiratory Medicine (871)
- Rheumatology (409)
- Sports Medicine (342)
- Surgery (448)
- Toxicology (53)
- Transplantation (185)
- Urology (165)